| Study Acronym | LAMDARCT |
| Trial Title | L-DOPA for neovascular (wet) age-related macular degeneration (AMD)? A Randomised Controlled Trial: LAMDARCT |
| Clinical Area | Ophthalmology |
| Trial Status | Set Up |
| Trial Registration |
-
Recruitment
Recruitment Target 360 Date Open to Recruitment Recruitment Date Closed to Recruitment -
Trial Design
Trial Design Prospective, randomised, pragmatic, multicentre, placebo-controlled clinical trial Study Aim To assess the effectiveness and cost-effectiveness of L-DOPA in patients being treated for wet AMD. Study Objectives
The specific objectives are to evaluate the effects of 24 months of L-DOPA in people newly diagnosed with wet AMD on:
1) Number of anti-VEGF injections
2) Distance and near visual acuity (VA)
3) Health-related and visual-related quality of life
4) Safety
5) Anatomical retinal findings indicative of disease activity
6) Costs and cost-effectiveness.
-
Chief Investigator (CI)
Chief Investigator Professor Tunde Peto, Queen’s University Belfast Email t.peto@qub.ac.uk -
Sponsor(s) & Funder(s)
Sponsor Belfast Health and Social Care Trust Funder National Institute for Health & Care Research Award NIHR167468